The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030. The slow growth can be attributed to the patent expiry of multiple biologics, increasing approval and penetration of biosimilars, and declining prices. For instance, PanGen Biotech Inc. is developing Erisa (PDA10). This erythropoietin biosimilar drug is under phase 3 clinical trial to check the safety and efficacy of the drug in patients with anemia.
The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.
Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.
Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others. In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.
This product will be delivered within 1-3 business days.
The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.
Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.
Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others. In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.
Erythropoietin Drugs Market Report Highlights
- By type, the biologics segment accounted for the largest share of the market in 2022. This can be attributed to the availability of FDA-approved EPO biologics for the treatment of cancer-induced anemia and CKD patients.
- Based on product, the erythropoietin segment dominated the EPO drugs market in 2022 owing to the higher number of approved products and higher prescription rate of erythropoietin.
- The renal diseases segment dominated the EPO drugs market in 2022. The high prevalence of CKD and the high prescription rate of EPO drugs are major factors contributing to the dominance of this segment. According to the National Kidney Foundation (NKF), 10% of the total population is affected by chronic kidney disease (CKD) worldwide.
- North America dominated the global market in 2022 owing to factors such as late approval and lower penetration of biosimilars in the market
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping for Type, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of chronic diseases
3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
3.3.2 Market Restraint Analysis
3.3.2.1 Patent expiration of branded drugs
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter’s Five Forces
3.4.1.1 Threat of new entrants: Moderate
3.4.1.2 Bargaining power of buyers: Moderate
3.4.1.3 Competitive rivalry: High
3.4.1.4 Threat of substitutes: High
3.4.1.5 Bargaining power of suppliers: Low
3.4.2 Industry Analysis: PESTEL
3.4.2.1 Political & Legal
3.4.2.2 Economical
3.4.2.3 Technological
3.5 Pipeline Analysis
Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)
4.1 Erythropoietin Drugs Market: Type Movement Analysis
4.1.1 Biologics
4.1.1.1 Biologics Market Estimates and Forecast, 2018 - 2030 (USD Million)
4.1.2 Biosimilars
4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)
5.1 Erythropoietin Drugs Market: Product Movement Analysis
5.1.1 Erythropoietin
5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.1.2 Darbepoetin-alfa
5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)
6.1 Erythropoietin Drugs Market: Application Movement Analysis
6.1.1 Cancer
6.1.1.1 Cancer Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
6.1.2 Renal Diseases
6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.1.3 Neurology
6.1.3.1 Neurology Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9.7 Rest of Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Key Country Dynamics
7.3.2.2 Target Disease Prevalence
7.3.2.3 Competitive Scenario
7.3.2.4 Regulatory Framework
7.3.2.5 Reimbursement Scenario
7.3.2.6 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Key Country Dynamics
7.3.3.2 Target Disease Prevalence
7.3.3.3 Competitive Scenario
7.3.3.4 Regulatory Framework
7.3.3.5 Reimbursement Scenario
7.3.3.6 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Key Country Dynamics
7.3.4.2 Target Disease Prevalence
7.3.4.3 Competitive Scenario
7.3.4.4 Regulatory Framework
7.3.4.5 Reimbursement Scenario
7.3.4.6 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5 Australia
7.3.5.1 Key Country Dynamics
7.3.5.2 Target Disease Prevalence
7.3.5.3 Competitive Scenario
7.3.5.4 Regulatory Framework & Reimbursement Scenario
7.3.5.5 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6 Thailand
7.3.6.1 Key Country Dynamics
7.3.6.2 Target Disease Prevalence
7.3.6.3 Competitive Scenario
7.3.6.4 Regulatory Framework & Reimbursement Scenario
7.3.6.5 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7 South Korea
7.3.7.1 Key Country Dynamics
7.3.7.2 Target Disease Prevalence
7.3.7.3 Competitive Scenario
7.3.7.4 Regulatory Framework & Reimbursement Scenario
7.3.7.5 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7.6 Rest of Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.1.1 Latin America Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.2 Brazil
7.4.2.1 Key Country Dynamics
7.4.2.2 Target Disease Prevalence
7.4.2.3 Competitive Scenario
7.4.2.4 Regulatory Framework
7.4.2.5 Reimbursement Scenario
7.4.2.6 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3 Mexico
7.4.3.1 Key Country Dynamics
7.4.3.2 Target Disease Prevalence
7.4.3.3 Competitive Scenario
7.4.3.4 Regulatory Framework
7.4.3.5 Reimbursement Scenario
7.4.3.6 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4 Argentina
7.4.4.1 Key Country Dynamics
7.4.4.2 Target Disease Prevalence
7.4.4.3 Competitive Scenario
7.4.4.4 Regulatory Framework
7.4.4.5 Reimbursement Scenario
7.4.4.6 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4.7 Rest of Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.1.1 Middle East & Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2 South Africa
7.5.2.1 Key Country Dynamics
7.5.2.2 Target Disease Prevalence
7.5.2.3 Competitive Scenario
7.5.2.4 Regulatory Framework
7.5.2.5 Reimbursement Scenario
7.5.2.6 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3 Saudi Arabia
7.5.3.1 Key Country Dynamics
7.5.3.2 Target Disease Prevalence
7.5.3.3 Competitive Scenario
7.5.3.4 Regulatory Framework
7.5.3.5 Reimbursement Scenario
7.5.3.6 Saudi Arabia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4 UAE
7.5.4.1 Key Country Dynamics
7.5.4.2 Target Disease Prevalence
7.5.4.3 Competitive Scenario
7.5.4.4 Regulatory Framework
7.5.4.5 Reimbursement Scenario
7.5.4.6 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5 Kuwait
7.5.5.1 Key Country Dynamics
7.5.5.2 Target Disease Prevalence
7.5.5.3 Competitive Scenario
7.5.5.4 Regulatory Framework
7.5.5.5 Reimbursement Scenario
7.5.5.6 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5.7 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 New Product Launch
8.1.2 Merger and Acquisition
8.1.3 Licensing Agreements
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of Key Distributors and Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Key Company Market Share Analysis, 2022
8.4.2 Company Market Position Analysis
8.4.3 Heat Map Analysis
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.5.2 Regional Network Map
8.6 Company Profiles
8.6.1. Johnson & Johnson Services, Inc.
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product Benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 Novartis AG
8.6.2.1 Company Overview
8.6.2.2 Financial Performance
8.6.2.3 Product Benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Teva Pharmaceutical Industries Ltd.
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Amgen, Inc.
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 F. Hoffmann-La Roche Ltd.
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 LG Chem
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Biocon
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Intas Pharmaceuticals Ltd.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Sun Pharmaceutical Industries Ltd.
8.6.8.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Dr. Reddy’s Laboratories Ltd
8.6.10.1 Company Overview
8.6.10.2 Product Benchmarking
8.6.10.3 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Erythropoietin Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 6 Global Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 8 North America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 10 North America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 11 North America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 12 U.S. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 13 U.S. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 14 U.S. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 15 Canada Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 16 Canada Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 17 Canada Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 18 Europe Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 19 Europe Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 20 Europe Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 21 Europe Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 22 Germany Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 23 Germany Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 24 Germany Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 25 U.K. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 26 U.K. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 27 U.K. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 28 France Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 29 France Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 30 France Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 31 Italy Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 32 Italy Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 33 Italy Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 34 Spain Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 35 Spain Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 36 Spain Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 37 Denmark Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 38 Denmark Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 39 Denmark Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 40 Sweden Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 41 Sweden Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 42 Sweden Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 43 Norway Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 44 Norway Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 45 Norway Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 50 Japan Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 51 Japan Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 52 Japan Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 53 China Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 54 China Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 55 China Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 56 India Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 57 India Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 58 India Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 59 South Korea Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 60 South Korea Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 61 South Korea Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 62 Australia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 63 Australia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 64 Australia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 65 Thailand Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 66 Thailand Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 67 Thailand Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 68 Latin America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 69 Latin America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 70 Latin America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 71 Latin America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 72 Brazil Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 73 Brazil Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 74 Brazil Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 75 Mexico Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 76 Mexico Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 77 Mexico Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 78 Argentina Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 79 Argentina Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 80 Argentina Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 88 South Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 89 South Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 90 South Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 91 UAE Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 92 UAE Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 93 UAE Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
Table 94 Kuwait Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 95 Kuwait Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
Table 96 Kuwait Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Erythropoietin drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot (By type, by product, and by application)
Fig. 11 Competitive landscape snapshot
Fig. 12 Penetration & growth prospect mapping for type, 2022
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Market restraint relevance analysis (Current & future impact)
Fig. 15 Erythropoietin drugs market: Type outlook and key takeaways
Fig. 16 Erythropoietin drugs market: Type movement analysis
Fig. 17 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Erythropoietin drugs market: Product outlook and key takeaways
Fig. 20 Erythropoietin drugs market: Product movement analysis
Fig. 21 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Darbepoetin - alfa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Erythropoietin drugs market: Application outlook and key takeaways
Fig. 24 Erythropoietin drugs market: Application movement analysis
Fig. 25 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Renal diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Regional Marketplace: Key Takeaways
Fig. 30 North America: SWOT analysis
Fig. 31 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 32 U.S. Key Country Dynamics
Fig. 33 U.S. Target Disease Prevalence
Fig. 34 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 35 Canada Key Country Dynamics
Fig. 36 Canada Target Disease Prevalence
Fig. 37 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Europe: SWOT analysis
Fig. 39 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 40 Germany Key Country Dynamics
Fig. 41 Germany Target Disease Prevalence
Fig. 42 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 43 U.K. Key Country Dynamics
Fig. 44 U.K. Target Disease Prevalence
Fig. 45 U.K. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 France Key Country Dynamics
Fig. 47 France Target Disease Prevalence
Fig. 48 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 49 Italy Key Country Dynamics
Fig. 50 Italy Target Disease Prevalence
Fig. 51 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 52 Spain Key Country Dynamics
Fig. 53 Spain Target Disease Prevalence
Fig. 54 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 55 Denmark Key Country Dynamics
Fig. 56 Denmark Target Disease Prevalence
Fig. 57 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 58 Sweden Key Country Dynamics
Fig. 59 Sweden Target Disease Prevalence
Fig. 60 Sweden Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Norway Key Country Dynamics
Fig. 62 Norway Target Disease Prevalence
Fig. 63 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 64 Rest of Europe Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Asia Pacific: SWOT Analysis
Fig. 66 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 67 Japan Key Country Dynamics
Fig. 68 Japan Target Disease Prevalence
Fig. 69 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 70 China Key Country Dynamics
Fig. 71 China Target Disease Prevalence
Fig. 72 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 73 India Key Country Dynamics
Fig. 74 India Target Disease Prevalence
Fig. 75 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 76 Australia Key Country Dynamics
Fig. 77 Australia Target Disease Prevalence
Fig. 78 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 79 South Korea Key Country Dynamics
Fig. 80 South Korea Target Disease Prevalence
Fig. 81 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 82 Thailand Key Country Dynamics
Fig. 83 Thailand Target Disease Prevalence
Fig. 84 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 85 Rest of APAC Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Latin America (LATAM): SWOT Analysis
Fig. 87 Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 88 Brazil Key Country Dynamics
Fig. 89 Brazil Target Disease Prevalence
Fig. 90 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 91 Mexico Key Country Dynamics
Fig. 92 Mexico Target Disease Prevalence
Fig. 93 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 94 Argentina Key Country Dynamics
Fig. 95 Argentina Target Disease Prevalence
Fig. 96 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 97 Rest of LATAM Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Middle East & Africa (MEA): SWOT Analysis
Fig. 99 Middle East & Africa (MEA) Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 100 South Africa Key Country Dynamics
Fig. 101 Target Disease Prevalence
Fig. 102 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 103 Saudi Arabia Key country dynamics
Fig. 104 Saudi Arabia Target Disease Prevalence
Fig. 105 Saudi Arabia Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 UAE Key Country Dynamics
Fig. 107 UAE Target Disease Prevalence
Fig. 108 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 109 Kuwait Key Country Dynamics
Fig. 110 Kuwait Target Disease Prevalence
Fig. 111 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 112 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 113 Heat Map Analysis
Fig. 114 Strategic Framework
Companies Mentioned
- Johnson & Johnson Services, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- LG Chem
- Biocon
- Intas Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 126 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 6.87 Billion |
| Forecasted Market Value ( USD | $ 7.8 Billion |
| Compound Annual Growth Rate | 1.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
